Kiadis Pharma (OTCMKTS:KIADF) Shares Down 2.1%

Shares of Kiadis Pharma (OTCMKTS:KIADFGet Rating) traded down 2.1% during mid-day trading on Monday . The stock traded as low as $6.41 and last traded at $6.41. 100 shares traded hands during trading, a decline of 94% from the average session volume of 1,800 shares. The stock had previously closed at $6.55.

The company’s 50-day moving average price is $6.41 and its two-hundred day moving average price is $6.41.

Kiadis Pharma Company Profile (OTCMKTS:KIADF)

Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. The company develops K-NK002 as an adjunctive immunotherapeutic, which is in Phase II clinical trials for blood cancer patients undergoing a haploidentical HSCT with the post-transplant cyclophosphamide (PTCy) protocol; and K-NK003, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia relapse/refractory (AML R/R).

Featured Stories

Want More Great Investing Ideas?

Receive News & Ratings for Kiadis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiadis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.